Regeneron Pharmaceuticals, Inc. with ticker code (REGN) have now 22 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $1,125.00 and $700.00 with the average target price sitting at $942.05. Given that the stocks previous close was at $902.69 this indicates there is a potential upside of 4.4%. Also worth taking note is the 50 day moving average now sits at $832.41 and the 200 day moving average is $797.34. The total market capitalization for the company now stands at 98.03B. The current share price for the company is: $899.82 USD
The potential market cap would be $102,307,209,358 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 25.64, revenue per share of $122.63 and a 9.21% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
